Is Albemarle Stock Outperforming the S&P 500?

Is Albemarle Stock Outperforming the S&P 500?

Tue, September 22, 2026 at 3:26 PM GMT+3 2 min read

• ALB -2.85%
• ^GSPC -0.75%

Headquartered in Charlotte, North Carolina, Albemarle Corporation (ALB) is a global specialty chemicals company that transforms essential resources into critical materials. It produces lithium- and bromine-based products that support mobility, energy storage, connectivity, and health applications, serving customers in about 70 countries. The company has a market capitalization of approximately $13 billion.

Companies valued between $10 billion and $200 billion are generally classified as "large cap stocks," and Albemarle comfortably fits this category. Its substantial market capitalization reflects its size, influence, and established presence in the specialty chemicals industry. From lithium resources to refining, Albemarle controls much of the journey behind critical battery materials. Its globally integrated operations support a reliable supply chain, while its specialty chemicals business adds diversification. Strong cash generation, innovation, and investments in sustainable products further strengthen its competitive position and long-term opportunities.

More News from Barchart

Despite these notable advantages, ALB is currently 48.9% below its 52-week high of $221, reached on June 7, 2026. Over the past three months, ALB shares have declined 29.6%, compared with the S&P 500's ($SPX) 3.5% gain over the same period.

Shares of ALB have declined 20.2% year-to-date, considerably underperforming the S&P 500's 13.4% gain. Over the past 52 weeks, though, ALB has advanced 38%, outpacing the S&P 500's 16.5% return over the same period.

ALB has traded below its 200-day moving average since late June and slipped below its 50-day moving average in early September, pointing to weakening momentum in the near term.

Albemarle's strong performance may have been supported by a sharp improvement in earnings and favorable lithium market conditions, alongside broader investor interest in critical minerals and efforts to strengthen domestic supply chains. In its second-quarter results, reported on Aug. 5, Albemarle posted adjusted EPS of $3.75, up more than 3,300% year over year and above the $3.20 analyst forecast. Revenue also rose 31.1% year over year to $1.74 billion, exceeding expectations of $1.61 billion.

Its adjusted EBITDA climbed 155% year over year to $858.1 million, and the adjusted EBITDA margin expanded to 49% from 25%. Albemarle also delivered roughly $100 million in cost and productivity improvements during the first half of 2026. The strong results were followed by a 5.5% jump in ALB shares in the next trading session.

Within the competitive specialty chemicals industry, top rival Linde plc (LIN) has delivered a mixed performance relative to ALB, gaining 7.3% year-to-date while trailing ALB over the past 52 weeks with a 4.5% return.

Wall Street analysts remain somewhat bullish on ALB's prospects. The stock carries a consensus "Moderate Buy" rating from the 22 analysts covering it, while the mean price target of $176.77 implies 56.5% upside from current levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com